Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia.
Yoshida N.
Int J Hematol. 2024 Mar;119(3):240-247. doi: 10.1007/s12185-023-03564-4. Epub 2023 Mar 3.
Marrow failure.
Bagby GC, Lipton JM, Sloand EM, Schiffer CA.
Hematology Am Soc Hematol Educ Program. 2004:318-36. doi: 10.1182/asheducation-2004.1.318.
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies.
Frigault MJ, Graham CE, Berger TR, Ritchey J, Horick NK, El-Jawahri A, Scarfò I, Schmidts A, Haradhvala NJ, Wehrli M, Lee WH, Parker AL, Wiggin HR, Bouffard A, Dey A, Leick MB, Katsis K, Elder EL, Dolaher MA, Cook DT, Chekmasova AA, Huang L, Nikiforow S, Daley H, Ritz J, Armant M, Preffer F, DiPersio JF, Nardi V, Chen YB, Gallagher KME, Maus MV.
Blood. 2024 Sep 12;144(11):1153-1167. doi: 10.1182/blood.2024024104.
Single Large-Scale Mitochondrial DNA Deletion Syndromes.
Goldstein A, Falk MJ.
2003 Dec 17 [updated 2023 Sep 28]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026.
Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.
Iguchi A, Cho Y, Sugiyama M, Terashita Y, Ariga T, Hosoya Y, Hirabayashi S, Manabe A, Hara K, Aiba T, Shiokawa T, Tada H, Sato N.
Int J Hematol. 2017 Aug;106(2):291-298. doi: 10.1007/s12185-017-2235-z. Epub 2017 Apr 11.
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial.
Shimamura A, Maschan A, Bennett C, Samarasinghe S, Farrar JE, Li CK, Sirachainan N, Pongtanakul B, Komvilaisak P, Zubarovskaya L, Rothman JA, Walkovich K, Nakano TA, Bertuch AA, Ferrao A, Bhat R, Hanna R, Overholt K, Boklan J, Wong TF, Wang Q, Urban P, Strahm B, Wang W, Vlachos A, Williams DA.
Blood Adv. 2025 Aug 12;9(15):3728-3738. doi: 10.1182/bloodadvances.2024015102.
Long-term outcomes of patients with refractory cytopenia of childhood under observation only.
Drexler B, Schwarz-Furlan S, Baumann I, Rudelius M, Nöllke P, Lebrecht D, Ramamoorthy S, Rotari N, Karow A, Hirabayashi S, Beier F, Behrens YL, Göhring G, Kalb R, Wlodarski MW, Strahm B, Erlacher M, Niemeyer CM, Yoshimi A.
Blood Adv. 2025 Aug 26;9(16):4279-4285. doi: 10.1182/bloodadvances.2025016136.
Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function.
Aluri J, Bach A, Kaviany S, Chiquetto Paracatu L, Kitcharoensakkul M, Walkiewicz MA, Putnam CD, Shinawi M, Saucier N, Rizzi EM, Harmon MT, Keppel MP, Ritter M, Similuk M, Kulm E, Joyce M, de Jesus AA, Goldbach-Mansky R, Lee YS, Cella M, Kendall PL, Dinauer MC, Bednarski JJ, Bemrich-Stolz C, Canna SW, Abraham SM, Demczko MM, Powell J, Jones SM, Scurlock AM, De Ravin SS, Bleesing JJ, Connelly JA, Rao VK, Schuettpelz LG, Cooper MA.
Blood. 2021 May 6;137(18):2450-2462. doi: 10.1182/blood.2020009620.
FLAG with Bortezomib in Children and Adolescents with Relapsed/Refractory Acute Myeloid Leukemia in a Resource-Limited Setting: A Single-Center Experience from India.
Dave D, Tak H, Trivedi M, Yadav R, Doctor C, Panchal H.
South Asian J Cancer. 2025 May 15;14(3):570-573. doi: 10.1055/s-0045-1809167. eCollection 2025 Jul.
Of gains and losses: SAMD9/SAMD9L and monosomy 7 in myelodysplastic syndrome.
Cammenga J.
Exp Hematol. 2024 Jun;134:104217. doi: 10.1016/j.exphem.2024.104217. Epub 2024 Apr 20.
